| 1. |
- Berman, F., et al.
(författare)
-
New grid scheduling and rescheduling methods in the GrADS Project
- 2005
-
Ingår i: International journal of parallel programming. - : Springer Science and Business Media LLC. - 0885-7458 .- 1573-7640. ; 33:3-Feb, s. 209-229
-
Tidskriftsartikel (refereegranskat)abstract
- The goal of the Grid Application Development Software (GrADS) Project is to provide programming tools and an execution environment to ease program development for the Grid. This paper presents recent extensions to the GrADS software framework: a new approach to scheduling workflow computations, applied to a 3-D image reconstruction application; a simple stop/migrate/restart approach to rescheduling Grid applications, applied to a QR factorization benchmark; and a process-swapping approach to rescheduling, applied to an N-body simulation. Experiments validating these methods were carried out on both the GrADS MacroGrid (a small but functional Grid) and the MicroGrid (a controlled emulation of the Grid).
|
|
| 3. |
- Schjesvold, F., et al.
(författare)
-
Cobimetinib Alone and Plus Venetoclax With/Without Atezolizumab in Patients With Relapsed/Refractory Multiple Myeloma
- 2023
-
Ingår i: Clinical Lymphoma, Myeloma and Leukemia. - : Elsevier BV. - 2152-2650. ; 23:1
-
Tidskriftsartikel (refereegranskat)abstract
- Introduction: Mitogen-activated protein kinase pathway mutations are present in >50% of patients with relapsed/refractory (R/R) multiple myeloma (MM). MEK inhibitors show limited single-agent activity in R/R MM; combination with B-cell lymphoma-2 (BCL-2) and programmed death-ligand 1 inhibition may improve efficacy. This phase Ib/II trial (NCT03312530) evaluated safety and efficacy of cobimetinib (cobi) alone and in combination with venetoclax (ven) with/without atezolizumab (atezo) in patients with R/R MM. Patients and Methods: Forty-nine patients were randomized 1:2:2 to cobi 60 mg/day on days 1–21 (n = 6), cobi 40 mg/day on days 1–21 + ven 800 mg/day on days 1–28 with/without atezo 840 mg on days 1 and 15 of 28-day cycles (cobi-ven, n = 22; cobi-ven-atezo, n = 21). Safety run-in cohorts evaluated cobi-ven and cobi-ven-atezo dose levels. Results: Any-grade common adverse events (AEs) with cobi, cobi-ven, and cobi-ven-atezo, respectively, included diarrhea (33.3%, 81.8%, 90.5%) and nausea (16.7%, 50.0%, 66.7%); common grade ≥3 AEs included anemia (0%, 22.7%, 23.8%), neutropenia (0%, 13.6%, 38.1%), and thrombocytopenia (0%, 18.2%, 23.8%). The overall response rate for all-comers was 0% (cobi), 27.3% (cobi-ven), and 28.6% (cobi-ven-atezo), and 0%, 50.0%, and 100%, respectively, in patients with t(11;14)+. Biomarker analysis demonstrated non-t(11;14) patient selection with NRAS/KRAS/BRAF mutation or high BCL-2/BCL-2-L1 ratio (>52% of the study population) could enrich for responders to the cobi-ven combination. Conclusions: Cobi-ven and cobi-ven-atezo demonstrated manageable safety with moderate activity in all-comers, and higher activity in patients with t(11;14)+ MM, supporting a biomarker-driven approach for ven in MM.
|
|
